Company: CERO
Filing Date: 2025-02-05
Form Type: S-1/A
Source: 0001213900-25-010230
Chunk: 211

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-05
Form: S-1/A
Chunk 211
---
Extended Deadline”), subject to certain conditions (the “Nasdaq Conditions”). Pursuant to the Nasdaq Conditions, the Company shall demonstrate compliance with the Bid Price Requirement and apply to transfer its listing to the Nasdaq Capital Market on or prior to January 22, 2025. The Company is also required to satisfy the $2.5 million stockholders’ equity requirement of the Nasdaq Capital Market (the “Stockholders’ Equity Requirement”) on or prior to the Extended Deadline, submit certain plans to Nasdaq and make certain disclosures. The Company intends to apply to transfer its listing to the Nasdaq Capital Market and expects the proceeds of this offering to contribute materially to the satisfaction of the Stockholders’ Equity Requirement. Warrant Issuances On December 23, 2024, the Company issued warrants to purchase an aggregate of 84,059 shares of Common Stock, with an exercise price of $5.61 per share, which was the closing price of the Common Stock on Nasdaq on December 20, 2024, to certain institutional investors as a condition to the exercise of Preferred Warrants held thereby. On January 6, 2025, the Company issued additional warrants to purchase an aggregate of 163,853 shares of Common Stock, with an exercise price of $5.82 per share, which was the closing price of the Common Stock on Nasdaq on January 3, 2025, to an institutional investor as a condition to the exercise of Preferred Warrants held thereby. Such number of shares gives effect to the Reverse Stock Split. Reverse Stock Split At 12:01 a.m. Eastern time on January 8, 2025, we effected the Reverse Stock Split pursuant to which each 100 shares of our Common Stock outstanding immediately prior thereto was converted into 1 share of our Common Stock outstanding immediately thereafter. Factors Affecting Our Performance The Company believes that its performance and future success depend on several factors that present significant opportunities for the Company but also pose risks and challenges. These include, among others:

| ● | the extent to which the Company develops, in-licenses or acquires other product candidates and technologies in its product candidate pipeline; |

| ● | the costs and timing of process development and manufacturing scale-up activities associated with the Company’s product candidates and other programs as the Company advances them through preclinical and clinical development; |

| ● | the number and development requirements of product candidates that the Company may pursue; |

| ● | the costs, timing and outcome of regulatory review of